Jupiter Life Line Hospitals Limited (JLHL) Fair Value & Analysis
Healthcare · IN · Market cap ₹95.2B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated yesterday
Share price +10.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹1,197 – ₹1,591 · fair‑value band ₹416.84 – ₹792.76 · the ₹1,453 price screens above the ₹582.53 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Jupiter Life Line Hospitals Limited (JLHL) currently trades at ₹1,453, while our model-based Fair Value estimate is ₹582.53 — implying the stock looks roughly 59.9% overvalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Jupiter Life Line Hospitals Limited generated revenue of ₹15.0B at a net margin of 12.9%. Revenue grew 4.2% year over year. It earns a return on equity of 13.4%. Net debt stands at ₹5.3B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Jupiter Life Line Hospitals Limited, a multi-specialty hospital, provides health care services under the Jupiter brand in India. The company offers treatments in the areas of bariatric surgery, breast care center, cardiac surgery, cardiology, chest medicine, dental care, dermatology, endocrinology and diabetes, ENT, gastroenterology, general surgery and minimal access surgery, hematology and BMT, HPB and surgical gastroenterology, infectious diseases, internal medicine, interventional radiology, mental health, nephrology, neurology, neurosurgery, nutrition and dietetics, Obs and gynecology, oncology, ophthalmology, organ transplant, orthopedics, pediatrics, pain clinic, plastic and cosmetic surgery, rehabilitation, rheumatology, robotic knee replacement, robotic surgery, TAVI/TAVR, and urology. It also operates hotel under the Fortune Park Lake City Hotel brand in Thane. The company was incorporated in 2002 and is based in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Jupiter Life Line Hospitals Limited reported revenue of ₹15.0B in FY2026 versus ₹7.3B in FY2022, a compound +19.6%/yr. Reported net income was ₹1.9B in FY2026, compounding +39.6%/yr from FY2022.
Is JLHL fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$95.75 | R$123.65 | +29% |
| Fresenius SE FSNUY | $11.47 | $8.55 | -25% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.71 MYR | 4.87 MYR | -44% |
| IHHHF IHHHF | $1.71 | $1.17 | -32% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.50 | R$46.04 | +42% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jupiter Life Line Hospitals Limited (JLHL) undervalued?
What is the fair value of JLHL?
What is the quality score of JLHL?
What is the revenue of Jupiter Life Line Hospitals Limited (JLHL)?
What is the net profit margin of JLHL?
Does Jupiter Life Line Hospitals Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.